Sage Therapeutics, Inc. (SAGE)
Stock Price Chart
Key Info
| Market Cap | 2.60B |
| Revenue (ttm) | 8.91M |
| Net Income (ttm) | -611.70M |
| Shares Out | 51.97M |
| EPS (ttm) | -11.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $50.00 |
| Previous Close | $50.27 |
| Change ($) | -0.27 |
| Change (%) | -0.54% |
| Day's Open | 50.36 |
| Day's Range | 49.42 - 50.97 |
| Day's Volume | 770,105 |
| 52-Week Range | 25.01 - 173.76 |
More Stats
| Market Cap | 2.60B |
| Enterprise Value | 1.87B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 51.97M |
| Float | 51.02M |
| EPS (basic) | -11.8 |
| EPS (diluted) | -11.80 |
| FCF / Share | -9.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 7.15M |
| Short Ratio | 12.14 |
| Short % of Float | 19.83% |
| Beta | 2.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 291.83 |
| PB Ratio | 3.52 |
| Revenue | 8.91M |
| Operating Income | -632.41M |
| Net Income | -611.70M |
| Free Cash Flow | -503.76M |
| Net Cash | 727.65M |
| Net Cash / Share | 14.00 |
| Gross Margin | -4,069.03% |
| Operating Margin | -7,101.70% |
| Profit Margin | -6,869.20% |
| FCF Margin | -5,657.07% |
| ROA | -35.24% |
| ROE | -62.97% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.87 | 90.27 | - | - | - | - | - | - |
| Revenue Growth | -92.39% | - | - | - | - | - | - | - |
| Gross Profit | 6.47 | 90.27 | - | - | - | - | - | - |
| Operating Income | -708 | -393 | -273 | -160 | -94.65 | -33.81 | -18.28 | -9.63 |
| Net Income | -680 | -373 | -270 | -159 | -94.50 | -33.81 | -18.28 | -9.63 |
| Shares Outstanding | 50.83 | 46.12 | 38.11 | 33.49 | 27.78 | 21.57 | 1.49 | 1.12 |
| Earnings Per Share | -13.38 | -8.08 | -7.09 | -4.75 | -3.40 | -1.67 | -12.26 | -8.62 |
| Operating Cash Flow | -529 | -261 | -219 | -119 | -70.68 | -27.04 | -17.52 | -8.93 |
| Capital Expenditures | -5.75 | -2.86 | -1.36 | -1.42 | -0.20 | -0.13 | - | -0.11 |
| Free Cash Flow | -534 | -264 | -221 | -120 | -70.88 | -27.17 | -17.52 | -9.04 |
| Cash & Equivalents | 1,011 | 925 | 520 | 398 | 187 | 128 | 8.11 | 2.84 |
| Total Debt | 37.09 | - | - | - | - | - | - | - |
| Net Cash / Debt | 974 | 925 | 520 | 398 | 187 | 128 | 8.11 | 2.84 |
| Assets | 1,084 | 953 | 530 | 405 | 189 | 130 | 8.53 | 3.00 |
| Liabilities | 139 | 89.73 | 54.46 | 36.01 | 15.32 | 7.78 | 2.36 | 1.42 |
| Book Value | 945 | 863 | 475 | 369 | 174 | 122 | -31.54 | -13.39 |
Company Profile
Company Details
| Full Name | Sage Therapeutics, Inc. |
| Country | United States |
| Employees | 675 |
| CEO | Jeffrey M. Jonas |
Stock Information
| Ticker Symbol | SAGE |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: SAGE |
| IPO Date | July 18, 2014 |
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.